Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8501693
APP PUB NO 20100144621A1
SERIAL NO

12375734

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AMYLIN PHARMACEUTICALS INC9360 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
ELI LILLY AND COMPANYLILLY CORPORATE CENTER PATENT DIVISION INDIANAPOLIS IN 46285

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kim, Dennis La Jolla, US 13 233
Trautmann, Michael Hamburg, DE 7 38

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation